SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/08/22 Rubius Therapeutics, Inc. S-3 6:1M Toppan Merrill/FA |
Document/Exhibit Description Pages Size 1: S-3 Registration Statement - Securities for a HTML 231K Transaction 2: EX-4.3 Instrument Defining the Rights of Security Holders HTML 200K 3: EX-4.4 Instrument Defining the Rights of Security Holders HTML 200K 4: EX-5.1 Opinion of Counsel re: Legality HTML 14K 5: EX-23.1 Consent of Expert or Counsel HTML 5K 6: EX-FILING FEES Filing Fees HTML 32K
tm2217583-1_s3 - none - 7.1875323s |
|
Delaware
(State or other jurisdiction of
incorporation or organization) |
| |
46-2688109
(I.R.S. Employer
Identification Number) |
|
| Large accelerated filer ☒ | | |
Accelerated filer ☐
|
| |
Non-accelerated filer ☐
|
| |
Smaller reporting company ☐
Emerging growth company ☐ |
|
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 3 | | | |
| | | | 5 | | | |
| | | | 6 | | | |
| | | | 7 | | | |
| | | | 8 | | | |
| | | | 13 | | | |
| | | | 19 | | | |
| | | | 20 | | | |
| | | | 23 | | | |
| | | | 26 | | | |
| | | | 26 | | | |
| | | | 26 | | | |
| | | | 27 | | |
|
SEC registration fee
|
| | | $ | 23,175 | | |
|
FINRA filing fee
|
| | | | * | | |
|
Legal fees and expenses
|
| | | | * | | |
|
Accounting fees and expenses
|
| | | | * | | |
|
Printing fees and expenses
|
| | | | * | | |
|
Transfer agent and trustee fees
|
| | | | * | | |
|
Miscellaneous
|
| | | | * | | |
|
Total
|
| | | $ | * | | |
Exhibit
No. |
| |
Description
|
| |||
| | 1.1* | | | | Form of Underwriting Agreement | |
| | 3.1 | | | | Amended and Restated Certificate of Incorporation of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant’s Form 8-K (File No. 001-38586) filed with the SEC on July 23, 2018) | |
| | 3.2 | | | | | |
| | 4.1 | | | | | |
| | 4.2 | | | | Second Amended and Restated Investors’ Rights Agreement among the Registrant and certain of its stockholders, dated February 23, 2018 (Incorporated by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1 (File No. 333-225840) filed on June 22, 2018) | |
| | 4.3 | | | | | |
| | 4.4 | | | | | |
| | 4.5* | | | | Form of Certificate of Designations | |
| | 4.6* | | | | Form of Warrant Agreement | |
| | 4.7* | | | | Form of Unit Agreement and Unit Certificate | |
| | 4.8* | | | | Form of Preferred Stock Certificate | |
| | 5.1 | | | | | |
| | 23.1 | | | | | |
| | 23.2 | | | | | |
| | 24.1 | | | | | |
| | 25.1** | | | |
Form T-1 Statement of Eligibility of Trustee for Senior Indenture under the Trust Indenture Act of
1939 |
|
| | 25.2** | | | | Form T-1 Statement of Eligibility of Trustee for Subordinated Indenture under the Trust Indenture Act of 1939 | |
| | 107 | | | | |
| | | | RUBIUS THERAPEUTICS, INC. | | |||
| | | | By: | | |
/s/ Pablo J. Cagnoni
|
|
|
Signature
|
| |
Title
|
| |
Date
|
|
|
/s/ Pablo J. Cagnoni
Pablo J. Cagnoni, M.D.
|
| | Chief Executive Officer, Director (Principal Executive Officer) | | | | |
|
/s/ Jose Carmona
|
| | Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | | | | |
|
/s/ Noubar B. Afeyan
Noubar B. Afeyan, Ph.D.
|
| | Chairman of the Board of Directors | | | | |
|
/s/ David R. Epstein
|
| | Director | | | | |
|
/s/ Francis Cuss
Francis Cuss, M.B., B.Chir, FRCP
|
| | Director | | | | |
|
/s/ Natalie Holles
|
| | Director | | | | |
|
/s/ Anne Prener
Anne Prener, M.D., Ph.D.
|
| | Director | | | |
|
Signature
|
| |
Title
|
| |
Date
|
|
|
Michael Rosenblatt, M.D.
|
| | Director | | | | |
|
Catherine A. Sohn, Pharm.D.
|
| | Director | | | | |
|
Jonathan R. Symonds, CBE
|
| | Director | | | |
This ‘S-3’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 6/8/22 | PRE 14A | ||
6/7/22 | ||||
3/31/22 | 10-Q | |||
12/31/21 | 10-K, 5 | |||
8/21/19 | EFFECT | |||
8/1/19 | S-3 | |||
2/23/18 | ||||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/09/22 Rubius Therapeutics, Inc. 10-Q 9/30/22 58:5.3M 8/09/22 Rubius Therapeutics, Inc. 10-Q 6/30/22 52:4.8M |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/24/22 Rubius Therapeutics, Inc. 8-K:1,7,9 5/20/22 11:206K Toppan Merrill/FA 5/13/22 Rubius Therapeutics, Inc. 8-K:5 5/12/22 10:196K Toppan Merrill/FA 5/10/22 Rubius Therapeutics, Inc. 10-Q 3/31/22 52:4.8M Toppan Merrill Bridge/FA 4/08/22 Rubius Therapeutics, Inc. 8-K:7,8,9 4/08/22 11:243K Toppan Merrill/FA 3/30/22 Rubius Therapeutics, Inc. DEF 14A 5/12/22 1:3.9M Toppan Merrill/FA 2/25/22 Rubius Therapeutics, Inc. 10-K 12/31/21 74:10M Toppan Merrill Bridge/FA 3/12/20 Rubius Therapeutics, Inc. 10-K 12/31/19 86:13M Toppan Merrill Bridge/FA 7/23/18 Rubius Therapeutics, Inc. 8-K:5,8,9 7/17/18 3:223K Toppan Merrill/FA 7/13/18 Rubius Therapeutics, Inc. 8-A12B 1:21K Toppan Merrill/FA 7/02/18 Rubius Therapeutics, Inc. S-1/A 7:1M Toppan Merrill-FA 6/22/18 Rubius Therapeutics, Inc. S-1 18:11M Toppan Merrill-FA |